Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report by Corrado, Giacomo et al.
CASE REPORT Open Access
Solitary pancreatic lymph node metastasis from









Background: We report the first case of isolated pancreatic lymph node recurrence in a locally advanced breast
cancer patient.
Case: A 41-year old woman underwent radical mastectomy according to Madden and removal of axillary lymph
nodes for multicentric infiltrating ductal carcinoma pathologically staged as pT2N2M0. After six years from primary
diagnosis, and four years from the diagnosis of lung recurrence, she developed an isolated metastatic lesion to
pancreatic lymph node. After surgical excision of metastasis, hormone therapy with Exemestane was begun. At 16
months of follow-up, the patient appears free of disease.
Conclusion: Because metastatization to visceral organ carries a very unfavorable prognosis, we think that the
clinical significance of the elevation of CA 15.3 serum levels in the early detection of recurrence and in monitoring
metastatic disease during follow-up, should be not underestimated.
Background
Breast cancer is one of the most common causes of can-
cer-related death in women [1]. Haematogenous metas-
tases to lung, bone, liver and brain represent the most
frequent sites of disease recurrence [2], and once they
occur patients’ clinical outcome is dismal.
Metastatic involvement of pancreas and its lymph
nodes from another site is uncommon and accounts for
approximately 2% of pancreatic malignancies [3]. In
large autopsy series the prevalence of pancreatic metas-
tases has been described to be as high as 6 to 11%, and
renal cell carcinoma appears to be the most common
primary tumor metastating to pancreas [4]
Metastatic involvement of pancreas from primary
breast cancer is exceptional [2]. No reports have been
previously published documenting metastatic involve-
ment of pancreatic lymph nodes. We report the first
case of isolated involvement of pancreatic lymph node
in a patient with diagnosis of breast cancer.
Case Presentation
A 41-year-old white woman presented in July 2003 with
two nodules in the upper quadrants of the left breast
and underwent radical mastectomy according to Mad-
den and removal of 18 axillary lymph nodes for a multi-
centric infiltrating moderately differentiated ductal
carcinoma (2 cm maximum diameter); lymphovascular
space invasion was positive, and 8 lymph nodes were
shown to contain malignant cells.
The tumor was positive for both estrogen receptors
(ER) (90%) and progesterone receptors (PR) (70%), nega-
tive for human epidermal growth factor receptor 2
(c-erbB-2), and positive for Ki-67 (15%). The tumor was
pathologically staged as pT2N2M0.
Postoperatively, the patient received 8 cycles of adju-
vant chemotherapy with Epirubicin (4 cycles) and Cyclo-
phosphamide, Methotrexate, Fluorouracil (CMF)
protocol (4 cycles) plus radiotherapy (44 Gy) to the left
hemithorax and left supraclavicular fossa. Treatment
continued with Leuprolide in a monthly dose of 3.75 mg
for two years, and Tamoxifen in a daily dose of 20 mg.
In March 2007, an increase in CA15-3 levels (54.9 U/
mL; reference level, < 30) was documented in the
absence of any sign of recurrence as assessed by ima-
ging. Thoracic computed tomographic (CT) scan
demonstrated a solitary small soft tissue mass of
approximately 10 mm of diameter located in the middle
lobe of the right lung attached to the mediastinal pleura.
A total body CT-PET was positive.
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the visceral pleura of upper lobe. Histology examina-
tions showed the presence of metastatic breast carci-
noma both in the middle lobe and visceral pleura of
upper lobe. The tumor was positive for both ER and PR,
and negative for c-erbB-2. Postoperatively, she received
6 cycles of chemotherapy with Docetaxel and hormone
therapy with Letrozole.
Follow-up was negative until March 2009, when a
novel increase of CA 15.3 (59.8 U/mL) was demon-
strated. Ultrasonography of the liver showed, at the level
of pancreatic head, a cystic lesion approximately 14 ×
13 mm in diameter, with internal septa with features
suggestive of intraductal papillary mucinous neoplasm.
Pancreatic magnetic resonance confirmed this suspicion.
Even if CT guided biopsy and a total body CT-PET
were negative, the patient was strongly motivated to
take away the pancreatic lesion, and a month later pan-
creaticoduodenectomy was performed; the postoperative
course was uneventful. Pathological examination
revealed a mucinous cystoadenoma of the pancreatic
(1 cm maximum diameter) with negative resection mar-
gins. Surprisingly and fortunately, a peripancreatic
lymph node removed during surgery (0.7 cm maximum
diameter) was shown to contain tumour cells of the
same histotype of primitive breast cancer and showing
both ER and PR positivity, apparently stronger mem-
brane signal for HER-2 (Figure 1), CK7 and 19 positivity
(data not shown). Tumor cells resulted consistently
negative for carcinoembryonic antigen (CEA) (data not
shown) and for breast tissue marker gross cyctic disease
fluid protein (GCDFP) (data not shown). Immunoreac-
tion for CDX-2 antigen used to discriminate tumors of
gastroenteric origin was negative (data not shown).
A re-joint evaluation of the slides was planned with
two independent pathologists who confirmed the
diagnosis.
Consequently, surgery tumour markers returned
quickly within the reference range. After a careful coun-
seling hormone therapy with Exemestane was begun
which is currently ongoing. At 16 months of follow-up,
the patient is free of disease.
Conclusions
We describe a patient with breast cancer that after six
years from primary diagnosis, and four years from the
diagnosis of lung recurrence, she developed an isolated
metastatic lesion to pancreatic lymph node. The pecu-
liarity of this study is that, to our knowledge, this is the
first case of isolated peripancreatic lymph node metasta-
sis from breast cancer, and that the definitive diagnostic
work up was decided only on the basis of the elevation
of CA 15-3 level. In fact, all diagnostic examinations,
including total body CT-PET scan and MRI of the pan-
creas, failed to show the real site of recurrence.
The usual sites of metastatic deposits from breast can-
cer include bone, liver, lymph nodes, lung and brain [5].
Pancreas is very rarely affected by metastasis from other
primaries; in the largest series published to date
(n = 973) of surgical specimens of pancreatic neoplasms
[6] 31 (3.1%) were secondary tumors, of which were 11
lymphomas, 7 carcinomas from the stomach, 6 from the
kidney, 2 from the lung, and 1 each from the liver, pros-
tate, ovary, and uterus, as well as a case of Merkel cell
carcinoma. In most cases, metastases developed after
the primary tumor had been diagnosed, while in 34% of
the cases they remained clinically silent and were docu-
mented only at autopsy as occult metastases [6]. Estab-
lishing the origin of neoplastic involvement of
pancreatic lymph node was based on immunohisto-
chemical results: indeed, in cancer of the breast cytoker-
atin (CK) 7 is required to be positive while CK-20
should be negative.
In our case there was a strong nuclear positivity for
ER and an apparently stronger membrane signal for
HER-2, in tumor embolisms. FISH analysis for HER-2,
however, showed no gene amplification (LSABPx, ×200).
Moreover, neoplastic embolization was present, high-
lighted by staining for CK7 and 19. Tumor cells resulted
consistently negative for CDX-2. On the basis of this
evidence, a relatively recent neoplastic colonization from
breast cancer to the pancreatic lymph node could be
hypothesized. As mentioned in the results, the suspicion
of breast cancer recurrence was based only on the eleva-
tion of CA 15-3 serum level observed in the absence of
any symptoms or imaging findings. According with the
current guidelines published in February 2009 by the
National Comprehensive Cancer Network (NCCN) [7],
the recommended strategy for early detection of
relapsed breast cancer involves history/physical exami-
nation, breast self-examination, mammography, and pel-
vic examination, while complete blood count, chemistry
panel, bone scan, chest radiograph, liver ultrasound, CT
scan, [18F]fluorodeoxyglucose PET scanning, magnetic
resonance imaging, and tumor markers (CEA, CA15-3,
TPA, etc) are not considered fundamental in the moni-
toring of breast cancer survivors.
However, several studies in the last decades have
emphasized the role of the assessment of specific and
appropriately used tumor markers as an easy, cheap,
and significantly accurate tool for the early detection of
distant metastases; recently, Nicolini et al. [8] showed
that CA 15-3 as well as CEA, and TPA assessment con-
tributes to an early diagnosis, which precedes by a few
months, on average, clinical and/or instrumental signs
of recurrent disease in 70% to 90% cases.
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Page 2 of 4Figure 1 Peripancreatic lymph node localization of breast carcinoma. A) In this picture pancreatic tissue is observed in the upper-left
corner. In the central portion the metastatic lymph node is observed. Lymph node measured 4×2 mm in section and presented heavily
metastatic involvement. The area indicated by the white square is magnified in B and C. The area indicated by the black square is shown in D
and E at higher magnification (hematoxylin and eosin, ×25). B) Virtually all neoplastic cells are strongly estrogen receptor positive (ER nuclear
specific signal; LSABPx, ×200). C) Many tumor cells show a delicate membrane decoration for HER-2 (LSABPx, ×200). D and E) Neoplastic
embolization is present, highlighted by staining for CK7 and 19 (data not shown). Note the strong nuclear positivity for ER (D) and the
apparently stronger membrane signal for HER-2 (E), in these embolisms. Immunohistochemical characterization was made using a labeled
streptavidin biotin peroxidase method (LSABPx). Visualization of the reaction was performed with the Dako LSAB 2 Kit peroxidase, containing
labeled streptavidin biotin for primary rabbit/mouse antibody and diaminobenzidine (DAB).
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Page 3 of 4We think that the clinical significance of the elevation
of CA 15.3 serum levels in the early detection of recur-
rence and in monitoring metastatic disease during fol-
low-up, should be not underestimated, thus leading to
plan a through instrumental diagnostic work-up and, in
selected cases, an histologic evaluation.
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